Orion Oyj (ORINY) Stock

About Orion Oyj

Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug formulation. Its operations extend across Finland, the Nordic region, wider Europe, North America, and various international markets. The company's diverse product portfolio encompasses both prescribed medications and over-the-counter (OTC) healthcare solutions. This includes notable offerings such as Nubeqa for prostate cancer therapy; Dexdor and Precedex, utilized as sedatives in intensive care settings; Stalevo and Comtess/Comtan addressing Parkinson's disease; Simdax for acute heart failure decompensation; and Fareston for breast cancer management. Additionally, a range of Easyhaler devices—like Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol—are provided for managing asthma and chronic obstructive pulmonary disease (COPD). Beyond human medicine, the firm supplies a suite of veterinary medications, including products such as Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. It also produces APIs for both proprietary and generic pharmaceutical products and offers specialized contract manufacturing capabilities. Furthermore, Orion Oyj distributes veterinary medicines manufactured by other global pharmaceutical entities. Its clientele spans a broad spectrum of healthcare stakeholders, from specialist and general physicians, veterinarians, and pharmacists to hospitals, healthcare centers, clinics, laboratories, and directly to consumers who own pets. Strategic alliances include a collaboration with Propeller Health aimed at integrating its Easyhaler® product range for asthma and COPD management with digital health solutions. Additionally, it holds a research collaboration and licensing deal with Alligator Bioscience AB (publ) focused on pioneering novel bispecific antibody-based cancer treatments. Established in 1917, Orion Oyj maintains its corporate headquarters in Espoo, Finland.

Orion Oyj is headquartered in FI.

Orion Oyj (ORINY) stock trades at $38.54 with a market capitalization of $21.69B. The stock is valued at a price-to-earnings (P/E) ratio of 18.22, price-to-book of 8.59, price-to-sales of 4.94. Over the past 52 weeks the stock has ranged between $30.89 and $42.75, and currently trades 9.8% below its 52-week high. It pays a dividend yielding 2.70%.

On profitability, Orion Oyj generates a return on equity (ROE) of 48.73% — well above the market average, a sign of a high-quality business, return on capital employed of 52.00%, an operating margin of 34.11%, a net profit margin of 27.12%.

In its most recent fiscal year, Orion Oyj reported annual revenue of $1.9B, net profit of $481.0M, revenue has compounded at 11.9% a year over the last five years, profit at 16.9% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.29 — a conservative balance sheet with little leverage risk, a current ratio of 1.77, total assets of $2.0B, $161.0M in cash and equivalents.

ORINY has an average daily trading volume of 158 shares, a beta of 0.29 (less volatile than the overall market).

Official website: www.orionpharma.com